Hyperlipoproteinemia laboratory findings: Difference between revisions
Hardik Patel (talk | contribs) No edit summary |
Hardik Patel (talk | contribs) No edit summary |
||
| Line 56: | Line 56: | ||
* [[Urinalysis]] | * [[Urinalysis]] | ||
Other tests that may be done include: | Other tests that may be done to have a definitive diagnosis include: | ||
Studies of cells called fibroblasts to see how the body absorbs LDL cholesterol | *Studies of cells called fibroblasts (to see how the body absorbs LDL cholesterol) | ||
Gene | *Gene analysis (to identify the defect associated with hyperlipidemia) | ||
*Receptor analysis | |||
=== Approach === | ===Approach=== | ||
Shown below is | Shown below is a diagnostic algorithm to diagnose hyperlipidemia.<ref name="pmid21291689">{{cite journal |author=Sniderman A, Tremblay A, Bergeron J, Gagné C, Couture P |title=Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B |journal=[[Journal of Clinical Lipidology]] |volume=1 |issue=4 |pages=256–63 |year=2007 |month=August |pmid=21291689 |doi=10.1016/j.jacl.2007.07.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S1933-2874(07)00197-3 |accessdate=2012-10-24}}</ref> | ||
<br> | <br> | ||
{{familytree/start}} | {{familytree/start}} | ||
Revision as of 18:58, 24 October 2012
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hardik Patel, M.D., Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Laboratory Findings
Complete Lipid Profile
The US National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) suggests screening asymptomatic individuals with a complete fasting lipid profile every 5 years, with a shorter interval for those with high-normal lipid levels and longer interval for low-risk individuals with low or normal lipid levels. Obtain complete lipid profile after 9 to 12-hour fast. The reference values according to ATP III classification for making the diagnosis and risk stratification are depicted below:
| Levels of total cholesterol (mg/dl) | |
| < 200 | Desirable |
| 200 - 239 | Borderline high |
| ≥ 240 | High |
| Levels of LDL cholesterol (mg/dl) | |
| < 100 | Optimal |
| 100 - 129 | Near optimal |
| 130 - 159 | Borderline high |
| 160 - 189 | High |
| ≥ 190 | Very high |
| Levels of HDL Cholesterol (mg/dl) | |
| < 40 | Low |
| ≥ 60 | High |
| Levels of serum triglycerides (mg/dl) | |
| < 150 | Normal |
| 150 - 199 | Borderline high |
| 200 - 499 | High |
| ≥ 500 | Very high |
Other Laboratory Tests
For careful medical evaluation, must take into consideration all medications (both prescription and over-the-counter medications) and perform following tests to rule out secondary hyperlipidemias:
- Random blood sugar
- HbA1c
- Serum thyroid-stimulating hormone
- Liver function tests
- Renal function tests
- Urinalysis
Other tests that may be done to have a definitive diagnosis include:
- Studies of cells called fibroblasts (to see how the body absorbs LDL cholesterol)
- Gene analysis (to identify the defect associated with hyperlipidemia)
- Receptor analysis
Approach
Shown below is a diagnostic algorithm to diagnose hyperlipidemia.[1]
| Hyperlipidemia | |||||||||||||||||||||||||||||||||||||||||
| Triglycerides > 75th Percentile | NO | Type IIa | |||||||||||||||||||||||||||||||||||||||
| YES | |||||||||||||||||||||||||||||||||||||||||
| Types I, IIb, IV, V | |||||||||||||||||||||||||||||||||||||||||
| Total Cholesterol/Apo B ratio ≥ 6.2 | NO | Types IIb, IV | |||||||||||||||||||||||||||||||||||||||
| YES | |||||||||||||||||||||||||||||||||||||||||
| Types I, III, V | |||||||||||||||||||||||||||||||||||||||||
| Triglycerides/Apo B ratio < 10.0 | NO | Types I, V | |||||||||||||||||||||||||||||||||||||||
| YES | |||||||||||||||||||||||||||||||||||||||||
| Type III | |||||||||||||||||||||||||||||||||||||||||
References
- ↑ Sniderman A, Tremblay A, Bergeron J, Gagné C, Couture P (2007). "Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B". Journal of Clinical Lipidology. 1 (4): 256–63. doi:10.1016/j.jacl.2007.07.006. PMID 21291689. Retrieved 2012-10-24. Unknown parameter
|month=ignored (help)